Cervomed Inc. (CRVO) has disclosed a new risk, in the Manufacturing category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cervomed Inc. faces the risk that changes in manufacturing methods or formulation for product candidates like neflamapimod could drive up development costs and delay regulatory approval. Such changes may alter clinical performance and force additional or bridging trials, extending timelines and jeopardizing commercialization and revenue generation prospects.
Overall, Wall Street has a Strong Buy consensus rating on CRVO stock based on 5 Buys.
To learn more about Cervomed Inc.’s risk factors, click here.